Experimental optimization and commercialization of gene editor offtarget assays
Ended Other Transaction Agreement Awarded Last action
- Contract number
- HR00112090139
- Awardee
-
Sequre DX Inc. UEI JB5DF7LB3P37
- Awarding agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Obligated
- $371,091
Award facts
- Contract value 100% obligated
- $371,091.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
- Place of performance
- Boston, MA 02116, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $371,091 |
About this award
The U.S. Defense Advanced Research Projects Agency (DARPA) awarded a $371,091.00 Other Transaction Agreement to Sequre DX Inc., a for-profit organization, for the "EXPERIMENTAL OPTIMIZATION AND COMMERCIALIZATION OF GENE EDITOR OFFTARGET ASSAYS" project. The contract is for work to be performed in Boston, MA and has a completion date of September 30, 2021. This contract is not set aside for any specific business type.
Quick answers
Who was awarded contract HR00112090139?
HR00112090139 was awarded to Sequre DX Inc. by Defense Advanced Research Projects Agency (Department of Defense) on September 30, 2020.
How much is contract HR00112090139 worth?
The government has obligated $371,091 on HR00112090139.
Was contract HR00112090139 competed?
The extent of competition for HR00112090139 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award